Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences commercializes FDA-approved sexual and reproductive health products for women’s health. Its product portfolio includes PHEXX® (lactic acid, citric acid and potassium bitartrate), a hormone-free contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, an oral antibiotic for bacterial vaginosis and trichomoniasis.
Company news commonly covers product sales, operating results, commercialization partnerships, distribution agreements and international regulatory activity for PHEXX and SOLOSEC. Updates also include manufacturing and supply arrangements, stockholder votes, capital-market actions and education or advocacy initiatives tied to women’s health communication.
Evofem Biosciences (NASDAQ: EVFM) has successfully extended the cumulative net sales covenant from its April 2020 Securities Purchase Agreement to June 30, 2023. This decision reflects investor confidence in the company's growth potential. Notably, Phexxi® prescriptions surged by 48% in Q3 2021 and saw a 30% rise in October 2021. The company anticipates improved gross-to-net revenue starting December 2021. The report emphasizes Evofem's focus on addressing unmet needs in women's health through innovative products.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in a fireside chat and hold one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The pre-recorded chat will be available on demand starting at 10:00 AM ET on November 22, 2021, for 90 days. Evofem focuses on innovative products for women's sexual and reproductive health, highlighted by their FDA-approved product, Phexxi®, a hormone-free contraceptive gel. For more details, visit evofem.investorroom.com/Piper2021.
Evofem Biosciences (NASDAQ: EVFM) reported its Q3 2021 financial results, highlighting a net product sales of $1.7 million and a notable 94% increase in new prescriptions for its hormone-free contraceptive, Phexxi, driven by the 'House Rules' DTC campaign featuring Annie Murphy. Total operating expenses rose by 5% to $45.1 million. The company expects to reduce operating expenses by $50 million in 2022. Despite a net loss of $74.1 million for the quarter, cash reserves were reported at $14.9 million.
Evofem Biosciences (NASDAQ: EVFM) announced the submission of its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS on November 10, 2021. This submission marks a critical step in expanding access to Femidence™ for women in Mexico and aligns with Evofem's 2020 Global Health Agreement with Adjuvant Capital. If approved, Femidence™ could be available in early 2023. The company aims to provide effective reproductive health solutions for low and middle-income countries.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:20 p.m. ET. The event will feature a fireside chat format in Track 2. Interested parties can access a live and archived webcast on the company’s website. Evofem is focused on women's reproductive health, with its FDA-approved product, Phexxi®, being a hormone-free contraceptive. One-on-one meetings can be arranged through Stifel for attendees.
Evofem Biosciences (NASDAQ: EVFM) will host a webcast and conference call on November 15, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results and business highlights. Investors can access the live and archived webcast through a link on their investor room page. Participation by phone is also available, and a replay will be provided for 24 hours after the call. Evofem focuses on women's sexual and reproductive health, with its primary product being Phexxi®, a hormone-free contraceptive gel.
Evofem Biosciences (NASDAQ: EVFM) reported promising results from its "House Rules" DTC campaign featuring Annie Murphy, aimed at promoting Phexxi, a hormone-free contraceptive. The campaign has achieved 2 billion media impressions and led to a 263% increase in website traffic. Key metrics show a 71% rise in sales and a 56% increase in new users for Phexxi in September compared to August 2021. Over 8,900 units of Phexxi were dispensed, with 7,839 prescriptions issued. The campaign targets women seeking alternatives to hormonal contraceptives.
Evofem Biosciences has announced a registered direct offering of 10,000 shares of Series B Convertible Stock at $1,000 per share, totaling approximately $10 million in gross proceeds. The sale will close in two tranches, with the initial closing occurring shortly after the announcement. Funds will support Phexxi® commercialization, the Phase 3 clinical trial 'EVOGUARD' for preventing chlamydia and gonorrhea, and general corporate purposes. The offering is part of Evofem's strategy to enhance shareholder value and maintain cash flow into Q1 2022.
Evofem Biosciences, Inc. (NASDAQ: EVFM) praised House leaders for advocating coverage of all FDA-approved contraceptives under the Affordable Care Act (ACA). CEO Saundra Pelletier recognized the importance of the House's letter, which requests senior Biden Administration officials to ensure compliance with ACA requirements. The company's product, Phexxi, is a hormone-free contraceptive gel approved by the FDA in May 2020. Evofem focuses on women's reproductive health solutions, including contraception and protection against STIs.
Evofem Biosciences (NASDAQ: EVFM) announced its CEO, Saundra Pelletier, will present at the LD Micro Main Event in Los Angeles from October 12-14, 2021. The presentation is scheduled for October 12 at 12:30 p.m. PT. The company recently launched a new campaign, "House Rules," on September 9, 2021, to promote its hormone-free contraceptive, Phexxi. The campaign has successfully increased media coverage, site traffic, and telehealth visits, enhancing Phexxi prescription growth. Interested parties can register for the virtual presentation via the company website.